Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.

Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, Rigal-Huguet F, Coiteux V, Varet B, Dubruille V, Lenain P, Rousselot P, Rea D, Guerci-Bresler A, Legros L, Liu J, Gardembas M, Ianotto JC, Turlure P, Johnson-Ansah H, Martiniuc J, Jardel H, Joly B, Zunic P, Henni T, Villemagne B, Berger MG, Cayssials E, Guilhot F, Larosa F, Guilhot J, Etienne G, Mahon FX.

Clin Cancer Res. 2019 Nov 15;25(22):6606-6613. doi: 10.1158/1078-0432.CCR-18-3373. Epub 2019 Jul 10.

PMID:
31292142
2.

Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC-based first-line treatment: Retrospective observations from the FILO group.

Guillermin Y, Herbaux C, Subtil F, Aurran-Schleinitz T, Cymbalista F, Letestu R, Leprêtre S, Vaudaux S, Laribi K, Leblond V, Defoi Y, Benchikh R, Salles G, Godmer P, Jardel H, Vallais F, Feugier P, Orsini F, Pegourié B, Lévy V, Michallet AS.

Am J Hematol. 2018 Jan;93(1):E24-E27. doi: 10.1002/ajh.24951. Epub 2017 Nov 17. No abstract available.

3.

Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.

Kraeber-Bodere F, Pallardy A, Maisonneuve H, Campion L, Moreau A, Soubeyran I, Le Gouill S, Tournilhac O, Daguindau E, Jardel H, Morineau N, Bouabdallah K, Gyan E, Moles MP, Gressin R, Berthou C, Sadot S, Moreau P, Deau B, Bodet-Milin C, Cazeau AL, Garin E, Salaun PY, Vuillez JP, Gouilleux-Gruart V, Barbet J, Wegener WA, Goldenberg DM, Lamy T, Soubeyran P.

Lancet Haematol. 2017 Jan;4(1):e35-e45. doi: 10.1016/S2352-3026(16)30168-5. Epub 2016 Dec 8.

PMID:
27964867
4.

The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma.

Hanf M, Chiron D, de Visme S, Touzeau C, Maisonneuve H, Jardel H, Pellat-Deceunynck C, Amiot M, le Gouill S.

BMC Cancer. 2016 Oct 14;16(1):802.

5.

Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience.

Bourcier J, Gastinne T, Leux C, Moreau A, Bossard C, Mahé B, Blin N, Dubruille V, Touzeau C, Voldoire M, Guillaume T, Peterlin P, Gallas P, Garnier A, Maisonneuve H, Moreau P, Juge-Morineau N, Jardel H, Chevallier P, Moreau P, Le Gouill S.

Ann Hematol. 2016 Aug;95(8):1287-93. doi: 10.1007/s00277-016-2705-z. Epub 2016 Jun 14.

PMID:
27297970
6.

Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.

Dimopoulos MA, Cheung MC, Roussel M, Liu T, Gamberi B, Kolb B, Derigs HG, Eom H, Belhadj K, Lenain P, Van der Jagt R, Rigaudeau S, Dib M, Hall R, Jardel H, Jaccard A, Tosikyan A, Karlin L, Bensinger W, Schots R, Leupin N, Chen G, Marek J, Ervin-Haynes A, Facon T.

Haematologica. 2016 Mar;101(3):363-70. doi: 10.3324/haematol.2015.133629. Epub 2015 Dec 11.

7.

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial.

Rodon P, Hulin C, Pegourie B, Tiab M, Anglaret B, Benboubker L, Jardel H, Decaux O, Kolb B, Roussel M, Garderet L, Leleu X, Fitoussi O, Chaleteix C, Casassus P, Lenain P, Royer B, Banos A, Benramdane R, Cony-Makhoul P, Dib M, Fontan J, Stoppa AM, Traullé C, Vilque JP, Pétillon MO, Mathiot C, Dejoie T, Avet-Loiseau H, Moreau P.

Haematologica. 2015 Feb;100(2):e56-9. doi: 10.3324/haematol.2014.110890. Epub 2014 Nov 14. No abstract available.

8.

Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center.

Loirat M, Chevallier P, Leux C, Moreau A, Bossard C, Guillaume T, Gastinne T, Delaunay J, Blin N, Mahé B, Dubruille V, Augeul-Meunier K, Peterlin P, Maisonneuve H, Moreau P, Juge-Morineau N, Jardel H, Mohty M, Moreau P, Le Gouill S.

Ann Oncol. 2015 Feb;26(2):386-92. doi: 10.1093/annonc/mdu515. Epub 2014 Nov 12.

9.

Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: a French multicenter study.

Néel A, Henry B, Barbarot S, Masseau A, Perrin F, Bernier C, Kyndt X, Puechal X, Weiller PJ, Decaux O, Ninet J, Hot A, Aouba A, Astudillo L, Berthelot JM, Bonnet F, Brisseau JM, Cador B, Closs-Prophette F, Dejoie T, de Korwin JD, Dhote R, Fior R, Grosbois B, Hachulla E, Hatron PY, Jardel H, Launay D, Lorleac'h A, Pottier P, Moulis G, Serratrice J, Smail A, Hamidou M.

Autoimmun Rev. 2014 Oct;13(10):1035-41. doi: 10.1016/j.autrev.2014.08.031. Epub 2014 Aug 23.

10.

[Vitamin D supplementation: A iatrogenic hypercalcemia concerning an HIV-infected patient with disseminated tuberculosis].

Lescoat A, Poinsignon Y, Dos Santos A, Cano Y, Floc'h F, Jardel H.

Presse Med. 2012 Dec;41(12 Pt 1):1299-301. doi: 10.1016/j.lpm.2012.05.028. Epub 2012 Sep 14. French. No abstract available.

PMID:
22981408
11.

Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience.

Avet-Loiseau H, Roussel M, Campion L, Leleu X, Marit G, Jardel H, Dib M, Decaux O, Lamy T, Tiab M, Cony-Makhoul P, Banos A, Lepeu G, Lifermann F, Macro M, Kolb B, Hulin C, Caillot D, Traulle C, Mathiot C, Royer B.

Leukemia. 2012 Jan;26(1):158-9. doi: 10.1038/leu.2011.176. Epub 2011 Jul 29. No abstract available.

PMID:
21799511
12.

[Pulmonary and cutaneous lesions].

Hudier L, Poinsignon Y, Dos Santos A, Lesourd A, Pouedras P, Godmer P, Jardel H.

Rev Med Interne. 2011 Nov;32(11):706-7. doi: 10.1016/j.revmed.2010.12.007. Epub 2011 Jan 20. French. No abstract available.

PMID:
21255879
13.

Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients.

Roland V, Bodet-Milin C, Moreau A, Gastinne T, Mahé B, Dubruille V, Maisonneuve H, Juge-Morineau N, Moreau P, Jardel H, Planche L, Mohty M, Moreau P, Harousseau JL, Kraeber-Bodéré F, Le Gouill S.

Bone Marrow Transplant. 2011 Mar;46(3):393-9. doi: 10.1038/bmt.2010.130. Epub 2010 May 31.

PMID:
20577223
14.

Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.

Bodet-Milin C, Touzeau C, Leux C, Sahin M, Moreau A, Maisonneuve H, Morineau N, Jardel H, Moreau P, Gallazini-Crépin C, Gries P, Gressin R, Harousseau JL, Mohty M, Moreau P, Kraeber-Bodere F, Le Gouill S.

Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1633-42. doi: 10.1007/s00259-010-1469-2. Epub 2010 Apr 29.

PMID:
20428863
15.

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.

Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Renaud M, Harousseau JL, Guillerm G, Chaleteix C, Dib M, Voillat L, Maisonneuve H, Troncy J, Dorvaux V, Monconduit M, Martin C, Casassus P, Jaubert J, Jardel H, Doyen C, Kolb B, Anglaret B, Grosbois B, Yakoub-Agha I, Mathiot C, Avet-Loiseau H; Intergroupe Francophone du Myélome.

Lancet. 2007 Oct 6;370(9594):1209-18.

PMID:
17920916
16.

[Periodic paralysis discovered in a 65-year-old woman: one case report].

Decaux O, Poinsignon Y, Rosenbaum D, Sternberg D, Bouissiere-Jardel J, Jardel H.

Rev Med Interne. 2003 Jan;24(1):55-8. French.

PMID:
12614859
17.

[Acquired von Willebrand disease and lymphoproliferative syndromes].

Hunault-Berger M, Rachieru P, Ternisien C, Jardel H, Zandecki M, Boasson M, Ifrah N.

Presse Med. 2001 Feb 10;30(5):209-12. French.

PMID:
12385052
18.

CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia.

Chevallier P, Penther D, Avet-Loiseau H, Robillard N, Ifrah N, Mahé B, Hamidou M, Maisonneuve H, Moreau P, Jardel H, Harousseau JL, Bataille R, Garand R.

Br J Haematol. 2002 Jan;116(1):142-50.

PMID:
11841407
19.

Early intensive therapy with autologous stem cell transplantation in high-risk Hodgkin's disease: long-term follow-up in 35 cases.

Moreau P, Milpied N, Rapp MJ, Moreau A, Bourdin S, Mahe MA, Dupas B, Le Tortorec S, Hamidou M, Maisoneuve H, Mahe B, Bulabois CE, Morineau N, Jardel H, Harousseau JL.

Leuk Lymphoma. 1998 Jul;30(3-4):313-24.

PMID:
9713963
20.

[Primary lymphoma of the thyroid gland. Diagnostic and therapeutic discussion. Apropos of 4 cases].

Ifrah N, Rohmer V, Saint-André JP, Jardel H, Boasson M, Bigorgne JC.

Ann Med Interne (Paris). 1988;139(5):344-8. Review. French.

PMID:
3059909
21.

[Multifocal hemangioendothelioma of the bone. Apropos of a case].

Jardel H, Meslier N, Foussard C, Ifrah N, Renier JC, Boasson M.

Rev Rhum Mal Osteoartic. 1986 Dec;53(12):727-32. French. No abstract available.

PMID:
3823779
22.

Management of Amanita phalloides poisoning by Bastien's regimen.

Dumont AM, Chennebault JM, Alquier P, Jardel H.

Lancet. 1981 Mar 28;1(8222):722. No abstract available.

PMID:
6163056

Supplemental Content

Loading ...
Support Center